GRFS (US) share price forecast & AI signal — Grifols, S.A
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in GRFS
Grifols, S.A is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a HOLD with low confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Grifols, S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin,...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $8.43 |
| 2026-11-05 | $8.46 |
| 2026-11-04 | $8.61 |
| 2026-11-03 | $8.56 |
| 2026-11-02 | $8.51 |
| 2026-10-30 | $8.10 |
| 2026-10-29 | $8.04 |
GRFS FAQ
Is Grifols, S.A (GRFS) a buy or sell this week?
The ACE Stock Bots machine-learning model rates GRFS a HOLD for the week of 2026-10-30 with low confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for GRFS?
Every week the model scores GRFS across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.